Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

Autor: John H Beigel, Yajing Bao, Joy Beeler, Weerawat Manosuthi, Alex Slandzicki, Sadia M Dar, John Panuto, Richard L Beasley, Santiago Perez-Patrigeon, Gompol Suwanpimolkul, Marcelo H Losso, Natalie McClure, Dawn R Bozzolo, Christopher Myers, H Preston Holley, Justin Hoopes, H Clifford Lane, Michael D Hughes, Richard T Davey, Michael Winnie, Dinh V Dinh, Raghu Seethala, Hiram Garcia, Joe Pouzar, Michael Seep, Ernie Riffer, Belinda Bart, Sadia Dar, Melanie Hoppers, Heather Rowe, Cameron Wolfe, Donna Desantis, Barr Baynton, Norman Markowitz, Zebediah A Stearns, Josalyn Cho, Marcy Goisse, Thomas A Wolf, Jennifer Kay, Nila Dharan, William Fitzgibbons, Mark Woodruff, Todd Bell, Thomas Lenzmeier, Robert Schooley, Marie-Carmelle Elie, Patricia Winokur, Robert Finberg, Christopher Hurt, Pablo Tebas, Fred R Sattler, Madhavi Ampajwala, Donald Batts, Mark Bloch, Richard Moore, Dominic Dwyer, Javier Romo-Garcia, Santiago Perez Patrigeon, Ana Patricia Rodríguez Zulueta, Ploenchan Chetchotisakd, Kiat Ruxrungtham, Anchalee Avihingsanon, Winai Ratanasuwan, Sergio Lupo, Liliana Trape, Laura M Macias, Gustavo Lopardo, Laura Barcelona, Analia Mykietuk, Maria F Alzogaray

Publikováno v: The Lancet. Infectious diseases

Summary Background Influenza continues to have a substantial socioeconomic and health impact despite a long established vaccination programme and approved antivirals. Preclinical data suggest that combining antivirals might be more effective than adm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862b46a545f37ada255312740288945c
https://pubmed.ncbi.nlm.nih.gov/28958679